Navigation Links
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Date:5/13/2008

Patients Treated with XIENCE V in SPIRIT III Trial Experience Better Long-Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients

Treated with TAXUS

BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Long-term data presented for the first time today from the SPIRIT III trial, Abbott's U.S. pivotal trial studying the XIENCE(TM) V Everolimus Eluting Coronary Stent System, demonstrated that XIENCE V continues to deliver clinically superior benefits for patients compared to the TAXUS(R) paclitaxel-eluting coronary stent system. In this trial of more than 1,000 patients, XIENCE V demonstrated a 45 percent reduction in the risk of major adverse cardiac events (MACE) and a 32 percent reduction in the risk of target vessel failure (cardiac events related to the treated vessel) at two years as compared to TAXUS. The SPIRIT III two-year results were presented by Gregg W. Stone, M.D., principal investigator of the SPIRIT III trial, during the late-breaking clinical trials session at EuroPCR 2008.

"Not only did XIENCE V clearly differentiate itself from the TAXUS stent in the first year after treatment, it has now demonstrated even more positive effects at two years in the SPIRIT III trial," said Dr. Stone, Columbia University Medical Center and chairman, Cardiovascular Research Foundation, New York. "As measured by clinically significant reductions in target vessel failure and MACE, XIENCE V demonstrated an even greater improvement in patient outcomes compared to TAXUS at two years than at one year, driven by numerically lower rates of heart attacks and lower observed rates of re-intervention of the target lesion. We also saw encouraging trends for lower observed rates of late and very late stent thrombosis in XIENCE V-treated patients, especially in those who discontinued dual antiplatelet therapy."

The SPIRIT III trial of 1,002 patients, which is the basis for the pre- market application of XIENCE V to
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
2. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
5. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
6. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
7. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
8. Drug-Eluting Stents Outperform Bare Stents in Heart Attack
9. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
10. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
11. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... N.C. , July 2, 2015 ... employees to capture critical product and market insights ... many benefits to employee-based studies, it is essential ... their own internal employees to capture critical business-related ... by benchmarking firm, Best Practices, LLC, most benchmarked ...
(Date:7/2/2015)... 2, 2015  Before you head outdoors with your family ... stay safe and healthy. Take steps to protect yourself from ... Protect Your Skin From the Sun ... increase your risk of skin cancer. To protect your skin ... possible, especially during midday hours. Wear a hat with a ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/nlfg34/cancer ) has announced ... and by Application - Forecast to 2020" report to their ... reach $13.1 Billion in 2020 from an estimated $7.1 Billion in ... is dominated by North America , followed by ... Rest of the World (RoW). The cancer diagnostics market in ...
Breaking Medicine Technology:Leveraging Employee Insights to Produce Cutting-Edge Market Research 2First Aid Summer Survival Tips from Nyack Hospital 2First Aid Summer Survival Tips from Nyack Hospital 3Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2
(Date:7/2/2015)... ... July 02, 2015 , ... ... Delivery Coalition met for the late June Web-based session, the speakers discussed the ... schemes and managing high-risk patients through coordinated care. , During the session, participants ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... Dr. Divakar R. Krishnareddy, M.D., to the orthopedic and spine surgery team at ... herniations, sprains, strains, bursitis, and tendonitis. Along with the spine and spine surgery, ...
(Date:7/2/2015)... , ... July 02, 2015 , ... ... executing them with care and precision. There is an art and science that ... the honor of successfully reshaping the facial features and lives of more than ...
(Date:7/2/2015)... ... 02, 2015 , ... Breakthrough technologies are now available in ... Kalika, founder of New York Dynamic Neuromuscular Rehabilitation & Physical Therapy Clinic ... of back, hip, knee and shoulder pain as well as sports injury disorders, ...
(Date:7/2/2015)... PA (PRWEB) , ... July 02, 2015 , ... ... Vaccine Research (CVR) recently received nearly $4 million through five federal grants ... develop vaccines and therapies against the deadly diseases. , The research will ...
Breaking Medicine News(10 mins):Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 2Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 4Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 2Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 3Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4
... that an immunosuppressive drug used in organ transplant cases ... lupus erythematosus (SLE). SLE results in inflammation of connective ... Its cause is unknown. The findings were announced today ... Rheumatology in Boston. , Our findings show this therapy ...
... over year growth driven by Loestrin 24 and Taclonex; Company ... updates full year 2007 financial guidance, ST. DAVID,S, ... announced its results for the quarter ended,September 30, 2007. Revenue in ... 16.3%, over the prior year quarter. The,primary drivers of the increase ...
... Nurses Organizing Committee Donate $10,000 and Send ... ... Nurses Organizing Committee/California Nurses Association have,donated $10,000 in support of RNs striking ... nurses from around the nation as part,of a solidarity caravan to join ...
... N.J., Nov. 9 Hooper Holmes,Inc. (Amex: HH ... financial results for the third quarter ended September 30,2007. ... to $60.6,million in the corresponding period of 2006. The ... 2007 of $10.6 million, or $(0.16) per share,compared to ...
... due to non-recurring event in 2007, net loss stable ... Canadian dollars unless otherwise noted), BELLEVILLE, ON, Nov. ... research-based, technology-driven Canadian,biopharmaceutical company, today announced financial results for ... 30, 2007. "We are also focused on the ...
... Financial Flexibility To Fund ... ... ) today announced its results for the third quarter and nine,months ended ... sales of approximately $42 million and a net loss of,approximately $29 million, ...
Cached Medicine News:Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:Nurses From Across Nation Join Solidarity Caravan in Support of Striking Kentucky RNs 2Health News:Hooper Holmes Announces Third Quarter 2007 Results 2Health News:Hooper Holmes Announces Third Quarter 2007 Results 3Health News:Hooper Holmes Announces Third Quarter 2007 Results 4Health News:Hooper Holmes Announces Third Quarter 2007 Results 5Health News:Hooper Holmes Announces Third Quarter 2007 Results 6Health News:Hooper Holmes Announces Third Quarter 2007 Results 7Health News:Bioniche Reports Fiscal 2008 First Quarter 2Health News:Bioniche Reports Fiscal 2008 First Quarter 3Health News:Bioniche Reports Fiscal 2008 First Quarter 4Health News:Bioniche Reports Fiscal 2008 First Quarter 5Health News:Bioniche Reports Fiscal 2008 First Quarter 6Health News:Bioniche Reports Fiscal 2008 First Quarter 7Health News:Bioniche Reports Fiscal 2008 First Quarter 8Health News:Bioniche Reports Fiscal 2008 First Quarter 9
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: